New cocktail targets tough leukemia mutations
Disease control
Recruiting now
This early-phase trial tests a new drug called revumenib alongside standard chemotherapy and another targeted drug (midostaurin) for adults newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (NPM1 and FLT3 mutations). The study aims to find a safe…
Phase: PHASE1 • Sponsor: Richard Stone, MD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC